Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Glioma × Naltrexone × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2 Substance Withdrawal Syndrome 1 Prostatic Neoplasms 1 Overweight 1 Obesity 1 Melanoma 1 Kidney Neoplasms 1 Glioma 1 Glioblastoma 1 Chronic Pain 1 Carcinoma, Lobular 1 Carcinoma, Intraductal, Noninfiltrating 1 Breast Carcinoma In Situ 1

Interventions

Temozolomide 42 Bevacizumab 38 Radiotherapy 16 Magnetic Resonance Spectroscopy 12 Irinotecan 11 Nivolumab 7 Everolimus 6 Radiation 5 Carboplatin 5 poly ICLC 4 pembrolizumab 4 X-Rays 4 Phantoms, Imaging 4 Erlotinib Hydrochloride 4 Carmustine 4 ribociclib 3 fluorodopa F 18 3 Vorinostat 3 Specimen Handling 3 Radiotherapy, Intensity-Modulated 3 Radiosurgery 3 Nuclear Medicine Department, Hospital 3 Modafinil 3 Lomustine 3 trametinib 2 selinexor 2 plerixafor 2 perampanel 2 palbociclib 2 lenvatinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01303835 2015-07-17

Low Dose Naltrexone for Glioma Patients

Duke University

Phase 2 Completed

110 enrolled 9 charts

Glioblastoma, Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡